Press Releases

Curemark LLC Reports Positive Phase III Results of CM-AT In Children With Autism

RYE, New York, Dec. 7, 2011 – Curemark LLC, a Rye, New York-based drug research and development company, today announced...

Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity

Curemark Reports Positive Results for Novel Compound CM-182 in Schizophrenia Mouse Model

Curemark Completes Enrollment of Phase III Autism Trials